EMEA-002669-PIP02-20
Key facts
Invented name |
Lorviqua
|
Active substance |
Lorlatinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0006/2021
|
PIP number |
EMEA-002669-PIP02-20
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Treatment of lung cancer
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Pfizer Europa MA EEIG
Email: PIP_Enquiries@pfizer.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|